345 related articles for article (PubMed ID: 34025067)
1. Stroma-targeting strategies in pancreatic cancer: Past lessons, challenges and prospects.
Polani F; Grierson PM; Lim KH
World J Gastroenterol; 2021 May; 27(18):2105-2121. PubMed ID: 34025067
[TBL] [Abstract][Full Text] [Related]
2. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
3. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
4. Pathophysiological role of microRNA-29 in pancreatic cancer stroma.
Kwon JJ; Nabinger SC; Vega Z; Sahu SS; Alluri RK; Abdul-Sater Z; Yu Z; Gore J; Nalepa G; Saxena R; Korc M; Kota J
Sci Rep; 2015 Jun; 5():11450. PubMed ID: 26095125
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
6. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts.
Liu H; Shi Y; Qian F
Adv Drug Deliv Rev; 2021 May; 172():37-51. PubMed ID: 33705881
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic cancer stroma: an update on therapeutic targeting strategies.
Hosein AN; Brekken RA; Maitra A
Nat Rev Gastroenterol Hepatol; 2020 Aug; 17(8):487-505. PubMed ID: 32393771
[TBL] [Abstract][Full Text] [Related]
8. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
9. Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions.
Lin W; Noel P; Borazanci EH; Lee J; Amini A; Han IW; Heo JS; Jameson GS; Fraser C; Steinbach M; Woo Y; Fong Y; Cridebring D; Von Hoff DD; Park JO; Han H
Genome Med; 2020 Sep; 12(1):80. PubMed ID: 32988401
[TBL] [Abstract][Full Text] [Related]
10. Silencing PCBP2 normalizes desmoplastic stroma and improves the antitumor activity of chemotherapy in pancreatic cancer.
Li Y; Zhao Z; Lin CY; Liu Y; Staveley-OCarroll KF; Li G; Cheng K
Theranostics; 2021; 11(5):2182-2200. PubMed ID: 33500719
[No Abstract] [Full Text] [Related]
11. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment.
Tarannum M; Vivero-Escoto JL
Adv Drug Deliv Rev; 2022 Aug; 187():114357. PubMed ID: 35605679
[TBL] [Abstract][Full Text] [Related]
12. Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts with Distinct IL6-Mediated Therapy Resistance in Pancreatic Cancer.
McAndrews KM; Chen Y; Darpolor JK; Zheng X; Yang S; Carstens JL; Li B; Wang H; Miyake T; Correa de Sampaio P; Kirtley ML; Natale M; Wu CC; Sugimoto H; LeBleu VS; Kalluri R
Cancer Discov; 2022 Jun; 12(6):1580-1597. PubMed ID: 35348629
[TBL] [Abstract][Full Text] [Related]
13. NDRG1 overcomes resistance to immunotherapy of pancreatic ductal adenocarcinoma through inhibiting ATG9A-dependent degradation of MHC-1.
Zhang Z; Song B; Wei H; Liu Y; Zhang W; Yang Y; Sun B
Drug Resist Updat; 2024 Mar; 73():101040. PubMed ID: 38228036
[TBL] [Abstract][Full Text] [Related]
14. Single-cell sequencing in pancreatic cancer research: A deeper understanding of heterogeneity and therapy.
Liu Z; Zhang Y; Wu C
Biomed Pharmacother; 2023 Dec; 168():115664. PubMed ID: 37837881
[TBL] [Abstract][Full Text] [Related]
15. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications.
Erkan M; Hausmann S; Michalski CW; Fingerle AA; Dobritz M; Kleeff J; Friess H
Nat Rev Gastroenterol Hepatol; 2012 Aug; 9(8):454-67. PubMed ID: 22710569
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of iCAF-derived osteoglycin predict favorable outcome in pancreatic cancer.
Dings MPG; Manoukian P; Waasdorp C; Quik JSE; Strijker M; Lodestijn SC; van Neerven SM; Moreno LF; de Oliveira RL; Bonsing BA; Bruno MJ; Busch OR; Doukas M; van Eijck CH; Mohammad NH; de Hingh IH; Molenaar QI; Besselink MG; Vermeulen L; Medema JP; van Laarhoven HWM; Bijlsma MF
Int J Cancer; 2023 Feb; 152(3):511-523. PubMed ID: 36069222
[TBL] [Abstract][Full Text] [Related]
17. Single-cell RNA-seq reveals dynamic change in tumor microenvironment during pancreatic ductal adenocarcinoma malignant progression.
Chen K; Wang Q; Li M; Guo H; Liu W; Wang F; Tian X; Yang Y
EBioMedicine; 2021 Apr; 66():103315. PubMed ID: 33819739
[TBL] [Abstract][Full Text] [Related]
18. Innate and adaptive immune-directed tumour microenvironment in pancreatic ductal adenocarcinoma.
Joseph AM; Al Aiyan A; Al-Ramadi B; Singh SK; Kishore U
Front Immunol; 2024; 15():1323198. PubMed ID: 38384463
[TBL] [Abstract][Full Text] [Related]
19. Tumor-Stroma IL1β-IRAK4 Feedforward Circuitry Drives Tumor Fibrosis, Chemoresistance, and Poor Prognosis in Pancreatic Cancer.
Zhang D; Li L; Jiang H; Li Q; Wang-Gillam A; Yu J; Head R; Liu J; Ruzinova MB; Lim KH
Cancer Res; 2018 Apr; 78(7):1700-1712. PubMed ID: 29363544
[TBL] [Abstract][Full Text] [Related]
20. Tumor-stroma TGF-β1-THBS2 feedback circuit drives pancreatic ductal adenocarcinoma progression via integrin α
Nan P; Dong X; Bai X; Lu H; Liu F; Sun Y; Zhao X
Cancer Lett; 2022 Mar; 528():59-75. PubMed ID: 34958892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
